fitforthem
about

scope and guide to the platform

—research groups

research groups network graph visualization

—repositories

catalog of the institutional repositories

—heritage

selection of collections, museum, cultural sites and ancient books

By continuing your visit to this site, you accept the use of essential cookies.

Read more
6533b7d6fe1ef96bd1265c69

RESEARCH PRODUCT

Pembrolizumab: a new Drug That Can Induce Exacerbations of Psoriasis.

C. Pujol-marcoRafael Botella-estradaR. Ballester-sánchezA. Sahuquillo-torralba

subject

Drugmedicine.medical_specialtyHistologybusiness.industrymedia_common.quotation_subjectMEDLINEDermatologyPembrolizumabAntibodies Monoclonal Humanizedmedicine.diseaseDermatologyPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPsoriasisMonoclonalmedicineHumansPsoriasisbusinessmedia_common
yearjournalcountryeditionlanguage
2015-04-24
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2453
EU flag

FORTHEM European University Alliance is co-funded by the European Union. FIT FORTHEM has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 101017248. The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission.

University of Jyväskylä logoUniversity of Jyväskylä's websiteUniversity of Burgundy logoUniversity of Burgundy's websiteUniversity of Mainz logoUniversity of Mainz's websiteUniversity of Palermo logoUniversity of Palermo's websiteUniversity of Latvia logoUniversity of Latvia's website
University of Agder logoUniversity of Agder's websiteUniversity of Opole logoUniversity of Opole's websiteUniversity of Sibiu logoUniversity of Sibiu's websiteUniversity of València logoUniversity of València's website
FORTHEM logoFORTHEM alliance's website